Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the European Medicines Agency has granted Advanced Therapy Medicinal Product classification for its novel stem cell drug ' Stempeucel ' which will be used for the treatment of Thromboangiitis Obliterans . The ATMP classification, approved by the committee for Advanced Therapies of the European Medicines Agency, will allow Stempeutics to commercialize the product 'Stempeucel' across the European Union region.
http://ift.tt/1EImtoW
http://ift.tt/1EImtoW
No comments:
Post a Comment